CLINICAL TRIALS AND OBSERVATIONS Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

نویسندگان

  • Richard L. Piekarz
  • Robin Frye
  • H. Miles Prince
  • Mark H. Kirschbaum
  • Jasmine Zain
  • Steven L. Allen
  • Elaine S. Jaffe
  • Alexander Ling
  • Maria Turner
  • Cody J. Peer
  • William D. Figg
  • Seth M. Steinberg
  • Sonali Smith
  • David Joske
  • Ian Lewis
  • Laura Hutchins
  • Michael Craig
  • A. Tito Fojo
  • John J. Wright
  • Susan E. Bates
چکیده

1Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services, Rockville, MD; 2Center for Cancer Research, NCI, Bethesda, MD; 3Peter MacCallum Cancer Centre, East Melbourne, Australia; 4City of Hope National Cancer Center, Duarte, CA; 5Hoftra North Shore–Long Island Jewish School of Medicine, Manhasset, NY; 6Diagnostic Radiology Department, NIH Clinical Center, Bethesda, MD; 7University of Chicago, Chicago, IL; 8Sir Charles Gairdner Hospital, Nedlands, Australia; 9Royal Adelaide Hospital, Adelaide, Australia; 10University of Arkansas for Medical Sciences, Little Rock, AR; and 11West Virginia University, Morgantown, WV

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

Patients with peripheral T-cell lymphomas (PTLs) have an extremely poor prognosis when relapsed or refractory to conventional chemotherapy. We have studied alemtuzumab, a humanized anti-CD52 monoclonal antibody, as therapy for patients with heavily pretreated and refractory PTL. Fourteen patients entered the study. All had clinical stage III or IV disease. Patients received a rapidly escalating...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Clinical and virologic characteristics of chronic active Epstein-Barr virus infection

Thirty patients with chronic active Epstein-Barr virus (CAEBV) infection were analyzed. The study group included 18 male and 12 female patients, ranging in age from 5 to 31 years with a mean age of 14.2 years. Not all patients had high titers of EBV-specific antibodies, but all patients had high viral loads in their peripheral blood (more than 102.5 copies/mg DNA). Fifty percent of the patients...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies

Hematologic malignancies are a heterogeneous group of conditions with an unclear etiology. We hypothesized that diabetes mellitus type 2 is associated with increased risk of developing lymphoma, leukemia, and myeloma. A literature search identified 26 studies (13 casecontrol and 13 cohort studies) evaluating such an association. Outcome was calculated as the odds ratio (OR) using a random effec...

متن کامل

Regular Article CLINICAL TRIALS AND OBSERVATIONS Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study

• CNS involvement at relapse/ progression in PTCL occurred at a frequency similar to what is seen in aggressive B-cell lymphomas. • Outcome after relapse is generally very poor in patients with PTCL and is not significantly altered by presence of CNS involvement at relapse. Central nervous system (CNS) relapse in non-Hodgkin lymphoma (NHL) carries a very poor prognosis. Risk factors and outcome...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation

Donor lymphocyte infusions (DLIs) induce potent graft versus tumor (GVT) effects for relapsed chronic myelogenous leukemia (CML) after allogeneic stem cell transplantation (SCT) but are disappointing for other diseases. Disease resistance can occur if donor T cells are not appropriately activated in vivo. Ex vivo T-cell activation might overcome diseaseinduced anergy and augment GVT activity. W...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2011